Use of Bile Acid Binding Resins to Decrease PFAS Levels Via Colesevalem in Veterans Study

ClinicalTrials.gov ID

NCT07592858

Lead Sponsor

University of Rhode IslandOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

50Estimated

Last Update Posted

May 18, 2026Actual

Start Date

Jul 1, 2026Estimated

Primary Completion Date

Apr 30, 2029Estimated

Completion Date

Sep 29, 2029Estimated

Official Title

Use of Bile Acid Binding Resins to Decrease Systemic Per- and Polyfluoroalkyl Substance (PFAS) Levels and Improve Serum Lipid Profiles in Veterans: PFAS Reduction in Veterans Via Colesevalem Study (PAVERS) Study

Brief Summary

The goal of this study is to test the efficacy and feasibility of Colesevelam administration (50% of the recommended dose) to reduce serum PFAS concentration in the Veteran population who have serum PFAS levels that exceed the National Academies Science criteria (PFASsix > 20 ng/ml) using a double blind-placebo controlled study. Based on PFAS prevalence in serum samples, we anticipate recruiting up to n=500 Veterans to meet the goal of n=50 study participants to receive intervention or placebo. The primary outcome will be initial and final PFAS content in serum (total and 7 individual PFAS). The secondary outcome will be initial and final serum biomarkers related to lipid metabolism. As an exploratory aspect to the proposal, we will also measure fecal PFAS, bile acids, and microbial diversity to examine associations between PFAS content and bile acid levels and microbiome. Fecal PFAS, bile acid content, and microbiome may also be measured.

Detailed Description

This double-blind randomized controlled trial has a extended open phase to test the use of oral Colesevelam (3 x 625 mg tablets qd) for 12 weeks to lower total serum PFAS levels in individuals with >20 ng/ml PFAS. After 12 weeks, participants assigned to placebo will have an opportunity to participate in the intervention of 12 weeks. Participants on the intervention will remain on the intervention for another 24 weeks.

• PFAS
• Environmental Exposures
• Occupational Exposure to Chemicals
• Military Exposure
• Burn Pit Exposure
• Forever Chemicals
• Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia
• Hyperlipidemia (E.G., Hypercholesterolemia)

• Colesevelam
• Placebo

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

Yes

Eligibility Criteria

Inclusion:

• Male or female Veterans aged 25- 65 who have serum PFAS >20 ng/ml exceeding National Academy of Science guidance.
• Written informed consent will be obtained.
• Outpatient.
• Agreeable to participate in sharable data and biorepository.

Exclusion:

• Under the age of 25 years
• Unable or unwilling to sign the informed consent statement and HIPAA Authorization form
• Females who are pregnant (confirmed by urine pregnancy test), nursing or planned pregnancy within study period.
• Patients with hypertriglyceridemia, vitamin deficient patients, hyperthyroidism and diabetic, pancreatitis and intestinal and bowel obstruction
• Be receiving any investigational drug other than Colesevelam or participating in any other investigational study.
• Significant medical illnesses that may limit the subject's ability to complete follow-up visits, in the opinion of the investigator.
• Be receiving any non-standard immunosuppression protocol or other non-standard treatment that could affect interpretation of the study results.
• Those with significant cardiovascular disease including treatment with inotropes.
• Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
• Active substance abuse if this, in the opinion of the investigator, will interfere with the subject's ability to adhere to the study protocol.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Crossover Assignment

Masking

Quadruple

Lead Sponsor

University of Rhode IslandOTHER

Collaborators

Louisville VA Medical CenterFED

University of LouisvilleOTHER

Congressionally Directed Medical Research ProgramsFED

Rodney.Sparks@va.gov(207) 623-8411

• Examining a Novel Gastrointestinal Intervention to Negate Environmental Toxicants (ENGINE)

  NCT07226440

  RecruitingInterventionalPhase 1Phase 2Updated Apr 24, 2026
• A Study of the Safety and Efficacy of Patients With Familial Hypercholesterolaemia Taking Colesevelam as add-on Therapy to Their Existing Medication

  NCT00655265

  CompletedInterventionalPhase 4Updated Feb 11, 2014
• Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis

  NCT01066364

  CompletedInterventionalPhase 2Updated Jul 21, 2020
• Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids

  NCT02111603

  CompletedInterventionalPhase 4Updated May 12, 2016
• Colesevelam Versus Placebo in Cholestatic Pruritus

  NCT00756171

  CompletedInterventionalPhase 2Phase 3Updated Dec 18, 2012
• A Multicenter, Active and Placebo-controlled Study of Enteric Coated Sevelamer in Patients With Mild to Moderate Hypercholesteremia

  NCT00690937

  CompletedInterventionalPhase 2Updated Mar 19, 2014